Cargando…
Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353821/ https://www.ncbi.nlm.nih.gov/pubmed/32654064 http://dx.doi.org/10.1007/s00415-020-10046-8 |
| _version_ | 1783557964040241152 |
|---|---|
| author | Woo, Marcel S. Steins, David Häußler, Vivien Kohsar, Matin Haag, Friedrich Elias-Hamp, Birte Heesen, Christoph Lütgehetmann, Marc Schulze zur Wiesch, Julian Friese, Manuel A. |
| author_facet | Woo, Marcel S. Steins, David Häußler, Vivien Kohsar, Matin Haag, Friedrich Elias-Hamp, Birte Heesen, Christoph Lütgehetmann, Marc Schulze zur Wiesch, Julian Friese, Manuel A. |
| author_sort | Woo, Marcel S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7353821 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73538212020-07-13 Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients Woo, Marcel S. Steins, David Häußler, Vivien Kohsar, Matin Haag, Friedrich Elias-Hamp, Birte Heesen, Christoph Lütgehetmann, Marc Schulze zur Wiesch, Julian Friese, Manuel A. J Neurol Letter to the Editors Springer Berlin Heidelberg 2020-07-11 2021 /pmc/articles/PMC7353821/ /pubmed/32654064 http://dx.doi.org/10.1007/s00415-020-10046-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editors Woo, Marcel S. Steins, David Häußler, Vivien Kohsar, Matin Haag, Friedrich Elias-Hamp, Birte Heesen, Christoph Lütgehetmann, Marc Schulze zur Wiesch, Julian Friese, Manuel A. Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients |
| title | Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients |
| title_full | Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients |
| title_fullStr | Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients |
| title_full_unstemmed | Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients |
| title_short | Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients |
| title_sort | control of sars-cov-2 infection in rituximab-treated neuroimmunological patients |
| topic | Letter to the Editors |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353821/ https://www.ncbi.nlm.nih.gov/pubmed/32654064 http://dx.doi.org/10.1007/s00415-020-10046-8 |
| work_keys_str_mv | AT woomarcels controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients AT steinsdavid controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients AT haußlervivien controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients AT kohsarmatin controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients AT haagfriedrich controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients AT eliashampbirte controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients AT heesenchristoph controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients AT lutgehetmannmarc controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients AT schulzezurwieschjulian controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients AT friesemanuela controlofsarscov2infectioninrituximabtreatedneuroimmunologicalpatients |